product
foreseehome-logo

A home-based monitoring program supporting earlier detection of wet AMD in intermediate dry AMD patients1

FDA-CLEARED and covered by Medicare and most private insurance

The progression from dry age-related macular degeneration (AMD) to wet AMD can occur rapidly and lead to severe vision loss if left undiagnosed and untreated. ForeseeHome allows physicians to detect wet AMD earlier, and help preserve functional vision in patients at risk by beginning treatment earlier.

Set up and daily tests are quick and easy for patients

watch
The patient takes a daily, 3-minute test per eye
watch
The patients daily test results are automatically sent to the Notal Vision Data Monitoring Center
watch
The physician’s office is alerted when a significant change from baseline occurs, which may indicate potential AMD progression
timely-alert-image

Timely alerts can lead to early treatment of wet AMD2

FDA Indication for Use

ForeseeHome® is intended for use in the detection and characterization of central and paracentral metamorphopsia (visual distortion) in patients with age-related macular degeneration as an aid in monitoring progression of disease factors causing metamorphopsia including, but not limited to choroidal neovascularization (CNV). It is intended to be used at home for patients with stable fixation.

The ForeseeHome AMD Monitoring Program is only available by physician order and is intended to be used as an addition to regular eye exams.

The technical component of the ForeseeHome AMD Monitoring Program is covered by Medicare, subject to its coverage requirements for the test, to assess patients with dry AMD who are at risk of developing wet AMD. Please refer to your local Medicare Administrative Contractor (MAC) for which the ordering physician resides concerning coverage availability for the physician professional services component of the test.

References: 1. Chew EY, Clemons TE, Bressler SB, et al; AREDS2-HOME Study Research Group. Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the Eye (HOME) study. Ophthalmology. 2014;121(2):535-544. 2. Data on File. Notal Vision, 2017.